Julio Vega concentrates on corporate and securities law, with an emphasis on venture capital transactions, mergers and acquisitions, public offerings such as IPOs, joint ventures, strategic alliances, and licensing transactions. Julio regularly counsels startups on equity-based compensation matters, equity finance strategy, executive employment arrangements, general business strategy and other general corporate issues.
Julio has experience advising on international financing transactions and is fluent in Spanish. In addition to counseling startups, Julio represents emerging growth companies and established businesses in all areas of technology, including advanced materials, biotechnology, e-commerce, nanotechnology, networking, software and telecommunications.
He is frequently invited to participate in professional events and speak on numerous topics, including securities laws, mergers and acquisitions, and public and private equity and debt financing.
Prior to joining Morgan Lewis, Julio was a partner in the Venture Capital, Mergers and Acquisitions practice of another international law firm.
Note: This list includes engagements completed prior to joining Morgan Lewis.
Venture Capital Financings — Represented many technology and emerging-growth companies in venture capital financings and in equity financings by corporate partners. Julio also has represented venture capital firms in connection with venture capital investments in portfolio companies.
Mergers & Acquisitions — Represented both public companies and private companies in a wide range of merger and acquisition transactions, including tender offers, exchange offers and going-private transactions
Public Offerings — Represented technology and emerging-growth companies in initial public offerings and secondary public offerings of equity securities. Julio has also represented issuers in connection with Rule 144A offerings of convertible debt securities.
Joint Ventures and Strategic Alliances — Represented biotechnology companies in numerous corporate collaborations and strategic alliances with major pharmaceutical companies and large biotechnology companies. Julio has also represented U.S. technology companies in connection with domestic and international joint ventures.
Licensing and Distribution Agreements — Represented biotechnology and other high technology companies in connection with many in-licensing and out-licensing transactions involving high technology products and enabling platform technology. Julio has also represented technology companies in connection with product manufacturing and distribution arrangements.
Analysts in Media
DisruptiveApps, Inc. (iJukebox)
Innovative Spinal Technologies Inc.
LeukoSite (acquired by Millenium Pharmaceuticals)
Massachusetts Eye & Ear Infirmary
Novazyme Pharmaceuticals (acquired by Genzyme)
Organ Recovery Systems
Radius Health (formerly known as Nuvios Inc.)
Rezolve Group Inc.
St. Michael’s Medical
Suntory Pharmaceutical Research Laboratories
Voice Signal Technology
University of Pennsylvania, 1985, Bachelor of Science
University of Pennsylvania Law School, 1988, Juris Doctor
Massachusetts Supreme Judicial Court
US District Court for the District of Massachusetts
Awards and Affiliations
American Bar Association
Massachusetts Bar Association
Boston Bar Association
Board of Advisers, Sequoia Pharmaceuticals Inc.
Chambers USA, America’s Leading Lawyers for Business(2007–2012, 2015)
Legal 500, Corporate (2012–2014)
Best Lawyers, Securities Law (2010–2012, 2015)
Best Lawyers, Venture Capital Law(2009–2012, 2014–2015)
Best Lawyers, Biotechnology Law (2009–2011)
Super Lawyers, Massachusetts (2004–2011, 2013–2014)
Lawdragon 500, Dealmakers in America (2007)
Chambers Global, noted for Life Sciences (2007)
LMG Life Sciences 2012, “LMG Life Sciences Star” for outstanding transactional work